|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
50693855
???header.onlineuser??? :
262
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"rukazenkov yuri"???jsp.browse.items-by-author.description???
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立臺灣大學 |
2015 |
AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.
|
Ramalingam, Suresh S.; Yang, James Chih-Hsin; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Rukazenkov, Yuri; Frewer, Paul; Cantarini, Mireille; Ghiorghiu, Serban; Janne, Pasi A.; 楊志新 |
| 國立臺灣大學 |
2013 |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
|
Wu, Yi-Long; Fukuoka, Masahiro; Mok, Tony S. K.; Saijo, Nagahiro; Thongprasert, Sumitra; Yang, James C. H.; Chu, Da-Tong; Yang, Jin-Ji; Rukazenkov, Yuri; 楊志新 |
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
